Tuning CpG motif position in nanostructured DNA for efficient immune stimulation
- PMID: 38651249
- DOI: 10.1002/biot.202300308
Tuning CpG motif position in nanostructured DNA for efficient immune stimulation
Abstract
It was previously demonstrated that polypod-like nanostructured DNA (polypodna) comprising three or more oligodeoxynucleotides (ODNs) were useful for the delivery of ODNs containing cytosine-phosphate-guanine (CpG) motifs, or CpG ODNs, to immune cells. Although the immunostimulatory activity of single-stranded CpG ODNs is highly dependent on CpG motif sequence and position, little is known about how the position of the motif affects the immunostimulatory activity of CpG motif-containing nanostructured DNAs. In the present study, four series of polypodna were designed, each comprising a CpG ODN with one potent CpG motif at varying positions and 2-5 CpG-free ODNs, and investigated their immunostimulatory activity using Toll-like receptor-9 (TLR9)-positive murine macrophage-like RAW264.7 cells. Polypodnas with the CpG motif in the 5'-overhang induced more tumor necrosis factor-α release than those with the motif in the double-stranded region, even though their cellular uptake were similar. Importantly, the rank order of the immunostimulatory activity of single-stranded CpG ODNs changed after their incorporation into polypodna. These results indicate that the CpG ODN sequence as well as the motif location in nanostructured DNAs should be considered for designing the CpG motif-containing nanostructured DNAs for immune stimulation.
Keywords: CpG motif; DNA nanostructure; immunostimulatory activity; polypod‐like nanostructured DNA.
© 2024 The Authors. Biotechnology Journal published by Wiley‐VCH GmbH.
References
REFERENCES
-
- Nishikawa, M., Tan, M., Liao, W., & Kusamori, K. (2019). Nanostructured DNA for the delivery of therapeutic agents. Advanced Drug Delivery Reviews, 147, 29.
-
- Malik, S., Asmara, B., Moscato, Z., Mukker, J. K., & Bahal, R. (2018). Advances in nanoparticle‐based Delivery. Current Pharmaceutical Design, 43, 5164.
-
- Xiang, D., Shigdar, S., Qiao, G., Wang, T., Kouzani, A. Z., Zhou, S. F., Kong, L., Li, Y., Pu, C., & Duan, W. (2018). Nucleic acid aptamer‐guided cancer therapeutics and diagnostics: The next generation of cancer medicine. Theranostics, 5, 23.
-
- Mendes, L. P., Pan, J., & Torchilin, V. P. (2017). Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules., 22, 1401.
-
- Chen, J., Tang, Y., Liu, Y., & Dou, Y. (2018). Nucleic acid‐based therapeutics for pulmonary diseases. Aaps Pharmscitech [Electronic Resource], 19, 3670.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources